OBJECTIVE: To assess the relative frequency of unique mutations and their associated characteristics in 97 individuals with mutations in progranulin (GRN), an important cause of frontotemporal lobar degeneration (FTLD). PARTICIPANTS AND DESIGN: A 46-site International Frontotemporal Lobar Degeneration Collaboration was formed to collect cases of FTLD with TAR DNA-binding protein of 43-kDa (TDP-43)-positive inclusions (FTLD-TDP). We identified 97 individuals with FTLD-TDP with pathogenic GRN mutations (GRN+ FTLD-TDP), assessed their genetic and clinical characteristics, and compared them with 453 patients with FTLD-TDP in which GRN mutations were excluded (GRN- FTLD-TDP). No patients were known to be related. Neuropathologic characteristics were confirmed as FTLD-TDP in 79 of the 97 GRN+ FTLD-TDP cases and all of the GRN- FTLD-TDP cases. RESULTS: Age at onset of FTLD was younger in patients with GRN+ FTLD-TDP vs GRN- FTLD-TDP (median, 58.0 vs 61.0 years; P < .001), as was age at death (median, 65.5 vs 69.0 years; P < .001). Concomitant motor neuron disease was much less common in GRN+ FTLD-TDP vs GRN- FTLD-TDP (5.4% vs 26.3%; P < .001). Fifty different GRN mutations were observed, including 2 novel mutations: c.139delG (p.D47TfsX7) and c.378C>A (p.C126X). The 2 most common GRN mutations were c.1477C>T (p.R493X, found in 18 patients, representing 18.6% of GRN cases) and c.26C>A (p.A9D, found in 6 patients, representing 6.2% of cases). Patients with the c.1477C>T mutation shared a haplotype on chromosome 17; clinically, they resembled patients with other GRN mutations. Patients with the c.26C>A mutation appeared to have a younger age at onset of FTLD and at death and more parkinsonian features than those with other GRN mutations. CONCLUSION: GRN+ FTLD-TDP differs in key features from GRN- FTLD-TDP.
OBJECTIVE: To assess the relative frequency of unique mutations and their associated characteristics in 97 individuals with mutations in progranulin (GRN), an important cause of frontotemporal lobar degeneration (FTLD). PARTICIPANTS AND DESIGN: A 46-site International Frontotemporal Lobar Degeneration Collaboration was formed to collect cases of FTLD with TAR DNA-binding protein of 43-kDa (TDP-43)-positive inclusions (FTLD-TDP). We identified 97 individuals with FTLD-TDP with pathogenic GRN mutations (GRN+ FTLD-TDP), assessed their genetic and clinical characteristics, and compared them with 453 patients with FTLD-TDP in which GRN mutations were excluded (GRN- FTLD-TDP). No patients were known to be related. Neuropathologic characteristics were confirmed as FTLD-TDP in 79 of the 97 GRN+ FTLD-TDP cases and all of the GRN- FTLD-TDP cases. RESULTS: Age at onset of FTLD was younger in patients with GRN+ FTLD-TDP vs GRN- FTLD-TDP (median, 58.0 vs 61.0 years; P < .001), as was age at death (median, 65.5 vs 69.0 years; P < .001). Concomitant motor neuron disease was much less common in GRN+ FTLD-TDP vs GRN- FTLD-TDP (5.4% vs 26.3%; P < .001). Fifty different GRN mutations were observed, including 2 novel mutations: c.139delG (p.D47TfsX7) and c.378C>A (p.C126X). The 2 most common GRN mutations were c.1477C>T (p.R493X, found in 18 patients, representing 18.6% of GRN cases) and c.26C>A (p.A9D, found in 6 patients, representing 6.2% of cases). Patients with the c.1477C>T mutation shared a haplotype on chromosome 17; clinically, they resembled patients with other GRN mutations. Patients with the c.26C>A mutation appeared to have a younger age at onset of FTLD and at death and more parkinsonian features than those with other GRN mutations. CONCLUSION: GRN+ FTLD-TDP differs in key features from GRN- FTLD-TDP.
Authors: Deepak M Sampathu; Manuela Neumann; Linda K Kwong; Thomas T Chou; Matthew Micsenyi; Adam Truax; Jennifer Bruce; Murray Grossman; John Q Trojanowski; Virginia M-Y Lee Journal: Am J Pathol Date: 2006-10 Impact factor: 4.307
Authors: Brendan J Kelley; Wael Haidar; Bradley F Boeve; Matt Baker; Neill R Graff-Radford; Thomas Krefft; Andrew R Frank; Clifford R Jack; Maria Shiung; David S Knopman; Keith A Josephs; Sotirios A Parashos; Rosa Rademakers; Mike Hutton; Stuart Pickering-Brown; Jennifer Adamson; Karen M Kuntz; Dennis W Dickson; Joseph E Parisi; Glenn E Smith; Robert J Ivnik; Ronald C Petersen Journal: Neurobiol Aging Date: 2007-10-18 Impact factor: 4.673
Authors: Odity Mukherjee; Jun Wang; Michael Gitcho; Sumi Chakraverty; Lisa Taylor-Reinwald; Shantia Shears; John S K Kauwe; Joanne Norton; Denise Levitch; Eileen H Bigio; Kimmo J Hatanpaa; Charles L White; John C Morris; Nigel J Cairns; Alison Goate Journal: Hum Mutat Date: 2008-04 Impact factor: 4.878
Authors: Matt Baker; Ian R Mackenzie; Stuart M Pickering-Brown; Jennifer Gass; Rosa Rademakers; Caroline Lindholm; Julie Snowden; Jennifer Adamson; A Dessa Sadovnick; Sara Rollinson; Ashley Cannon; Emily Dwosh; David Neary; Stacey Melquist; Anna Richardson; Dennis Dickson; Zdenek Berger; Jason Eriksen; Todd Robinson; Cynthia Zehr; Chad A Dickey; Richard Crook; Eileen McGowan; David Mann; Bradley Boeve; Howard Feldman; Mike Hutton Journal: Nature Date: 2006-07-16 Impact factor: 49.962
Authors: Ian R A Mackenzie; Matt Baker; Stuart Pickering-Brown; Ging-Yuek R Hsiung; Caroline Lindholm; Emily Dwosh; Jennifer Gass; Ashley Cannon; Rosa Rademakers; Mike Hutton; Howard H Feldman Journal: Brain Date: 2006-11 Impact factor: 13.501
Authors: Baber K Khan; Josh D Woolley; Steven Chao; Tricia See; Anna M Karydas; Bruce L Miller; Katherine P Rankin Journal: Psychosomatics Date: 2012-01-28 Impact factor: 2.386
Authors: Leonel T Takada; Valeria S Bahia; Henrique C Guimarães; Thais V M M Costa; Thiago C Vale; Roberta D Rodriguez; Fabio H G Porto; João C B Machado; Rogério G Beato; Karolina G Cesar; Jerusa Smid; Camila F Nascimento; Lea T Grinberg; Sonia M D Brucki; Jessica R Maximino; Sarah T Camargos; Gerson Chadi; Paulo Caramelli; Ricardo Nitrini Journal: Alzheimer Dis Assoc Disord Date: 2016 Oct-Dec Impact factor: 2.703
Authors: Defne A Amado; Julianne M Rieders; Fortunay Diatta; Pilar Hernandez-Con; Adina Singer; Jordan T Mak; Junxian Zhang; Eric Lancaster; Beverly L Davidson; Alice S Chen-Plotkin Journal: Mol Ther Date: 2018-11-17 Impact factor: 11.454